RBC Capital Comments Following Weakness in Shares of Aerie Pharma (AERI)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting
March 3, 2016 8:30 AM ESTIRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for glaucoma and other diseases of the eye, today announced availability of two paper abstracts and two poster abstracts scheduled to be presented at the American Glaucoma Society (AGS) 26th Annual Meeting, taking place March 3-6, 2016, in Fort Lauderdale, Florida. The abstracts are now posted on the Aerie Pharmaceuticals website at... More
